CD274 and non-small cell lung carcinoma: Studies have shown higher frequencies of genetic mutations and PD-L1–positive expression in PSC than in conventional NSCLC, and PD-L1 positivity might lead to survival benefits from immunotherapy or even a favorable response in those harboring actionable mutations (4, 8, 9).